Skip to main content

Detroit R&D Reels in $800K SBIR Grant for Microarray Technology

NEW YORK (GenomeWeb News) – Detroit R&D has landed an $800,000 grant to continue developing its technology for screening a biomarker for prostate cancer, the company said today.
 
Under the two-year Phase II Small Business Innovation Research award, Detroit R&D will pursue research into ELISA and microarray kits to screen non-steroidal inflammatory drug-activated gene, or NAG-1, also known as macrophage inhibitory cytokine-1 or prostate-derived factor-15.
 
The microarray kits will measure levels of mature NAG-1 or H6D polymorphism in serum for early detection of prostate cancer. The kit also will be developed to stage and monitor prostate cancer and treatment.
 
The company received $1.2 million in SBIR funding in 2003 to develop microarray-based drug screening tools and to support research into biomarkers for fetal alcohol syndrome.
 
 

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.